Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET/CT to assess early response to Tarceva in advanced NSCLC
2005-004508-35Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Early response or progression by PET/CT at 6 weeks. Started Oct 2005; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-004508-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004508-35.